Strong top-line growth and margin expansion are positives, but widening losses and cash burn persist. Guidance unchanged suggests management is confident in H2 improvements from IRRAS synergies. Monitor cash runway and next quarter's op. leverage progress; any sign of cash burn acceleration would be concerning.
Price Chart
Executive Summary
ClearPoint Neuro reported Q1 2026 revenue of $12.1M (+43% YoY), beating pre-release consensus? (no explicit consensus but beat prior year), but EPS of -$0.32 missed the Street consensus of -$0.28. Gross margin expanded to 64%, but operating expenses grew 44% and net loss widened to $9.6M. Guidance for full-year 2026 revenue of $52-56M was maintained.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $12.1M, +43% YoY (16% organic), record quarter
- GAAP EPS -$0.32 vs consensus -$0.28 (miss of 14.3%)
- Gross margin 64%, up from 60% in Q1 2025
- Operating expenses $16.2M, +44% YoY, driven by IRRAS integration and headcount
- Net loss $9.6M vs $6.0M in Q1 2025
- Cash and equivalents $35.6M at March 31, 2026 (down from $45.9M at Dec 31, 2025)
- Full-year 2026 revenue guidance maintained at $52-56M
- Company expects cost synergies from IRRAS to reduce cash burn in H2 2026 and targets cash neutrality by 2027
Financial Impact
Revenue beat prior year by $3.6M, but net loss increased by $3.5M; EPS miss by $0.04 vs consensus
Risk Factors
- Integration of IRRAS may not deliver expected cost synergies on time
- Cash burn could accelerate if revenue growth slows or expenses continue to outpace revenue
- Dependence on biopharma partner programs and clinical trial progress for future revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-221596 |
| Document: clpt-20260513.htm | 0001193125-26-221596 |
| Document: clpt-ex99_2.htm | 0001193125-26-221596 |
| Document: 0001193125-26-221596-index-headers.html | 0001193125-26-221596 |
| Document: 0001193125-26-221596-index.html | 0001193125-26-221596 |
| Document: 0001193125-26-221596.txt | 0001193125-26-221596 |
| 8-K Data (Synthetic) | 0001193125-26-221596 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 21, 2026 22w ago | 8-K | $11.44 $17.22 | ▲ +50.52% | ▲ +51.94% | $9.04 (−20.98%) |
May 20, 2026 22w ago | 144 | $11.70 $17.06 | ▲ +45.81% | ▲ +45.48% | $9.04 (−22.74%) |
May 13, 2026 23w ago | 8-K | $12.77 $13.44 | ▲ +5.25% | ▲ +6.10% | $9.04 (−29.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers